Boston Scientific Corporation $BSX Holdings Boosted by State of Alaska Department of Revenue

State of Alaska Department of Revenue lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 11.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 162,750 shares of the medical equipment provider’s stock after buying an additional 17,115 shares during the quarter. State of Alaska Department of Revenue’s holdings in Boston Scientific were worth $7,104,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in BSX. BlackRock Inc. acquired a new stake in Boston Scientific in the second quarter valued at $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific during the 2nd quarter valued at $2,156,233,000. Janus Henderson Group PLC boosted its stake in Boston Scientific by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 12,589,385 shares of the medical equipment provider’s stock valued at $1,200,404,000 after acquiring an additional 617,515 shares during the last quarter. Amundi grew its holdings in Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock worth $886,213,000 after acquiring an additional 1,707,754 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock worth $871,702,000 after acquiring an additional 2,856,040 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 2.7%

BSX stock opened at $44.17 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $41.38 and a 1-year high of $105.65. The firm has a fifty day moving average price of $46.16 and a two-hundred day moving average price of $49.80. The firm has a market cap of $64.02 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 1.04 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific Corporation will post 3.24 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Jefferies Financial Group dropped their target price on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. BTIG Research reduced their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday, September 9th. JPMorgan Chase & Co. decreased their price target on Boston Scientific from $80.00 to $56.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Piper Sandler lowered their price objective on Boston Scientific from $65.00 to $60.00 in a report on Wednesday, July 29th. Finally, Leerink Partners cut their price objective on Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $68.23.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney acquired 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director David Habiger bought 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 194,522 shares of company stock valued at $9,385,210 in the last quarter. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.